# Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-20 mg/100 μCi Anaprazole Sodium Enteric-coated Capsule in Healthy Adult Male Subjects

> **NCT04476394** · PHASE1 · UNKNOWN · sponsor: **Sihuan Pharmaceutical Holdings Group Ltd.** · enrollment: 6 (estimated)

## Conditions studied

- Healthy Male Volunteers

## Interventions

- **DRUG:** [14C]-Anaprazole Sodium enteric-coated capsule

## Key facts

- **NCT ID:** NCT04476394
- **Lead sponsor:** Sihuan Pharmaceutical Holdings Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-03
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2020-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476394, "Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-20 mg/100 μCi Anaprazole Sodium Enteric-coated Capsule in Healthy Adult Male Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04476394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*